MAPT and Alzheimer disease: For the most common tauopathy, AD, the CSF biomarkers amyloid-β (Aβ) and total and phosphorylated tau have been used to aid diagnosis1–8 and these biomarkers are useful for assessing the outcome of therapies in clinical trials9–11.